The TULSA Procedure, performed with the TULSA-PRO system, represents a significant advancement in prostate care. It employs robotically controlled directional ultrasound to precisely heat prostate tissue to a 'kill temperature' of 55-57°C, while safeguarding surrounding nerves and anatomy. This innovative approach allows for real-time MRI thermography, enabling continuous visualization and autonomous temperature adjustments throughout the procedure. As a result, patients experience minimal side effects, no procedural blood loss, and a quicker return to their daily lives compared to traditional surgical methods.
During the SIR meeting, the TULSA Procedure will be highlighted in a session titled "Men's Health 1" on April 12, featuring five oral presentations from leading experts in the field. Notable presentations include Dr. Joseph J. Busch, Jr., who will discuss robotic-assisted MRI-guided transurethral ultrasound ablation for MRI-visible prostate cancer, and Dr. Steven S. Raman, who will present a featured abstract on automated prostate segmentation for MRI-guided ultrasound ablation.
Profound Medical's CEO, Arun Menawat, expressed enthusiasm about the company's significant presence at the SIR 2026 meeting, emphasizing the potential of the TULSA Procedure to transform treatment for prostate diseases. He noted that awareness and acceptance of the procedure's strong clinical profile are on the rise, and the company aims to build on this momentum by showcasing data from the CAPTAIN trial and real-world physician experiences throughout 2026.
As a commercial-stage medical device company, Profound Medical is committed to advancing MRI-guided therapies that improve clinical outcomes and patient experiences. The TULSA Procedure exemplifies this commitment, offering a personalized treatment strategy that minimizes the risks typically associated with surgery or radiation therapy. With its growing recognition in the medical community, the TULSA Procedure is poised to become a mainstream treatment option for men facing prostate disease.
